Patterns of disease, treatment, and outcomes of esophageal cancer arising within a previous radiation treatment field.

Authors

null

Lucy Xiaolu Ma

Princess Margaret Cancer Centre, Toronto, ON, Canada

Lucy Xiaolu Ma , Peiran Sun , Osvaldo Espin-Garcia , Chihiro Suzuki , Di Maria Jiang , Charles Henry Lim , Kirsty Taylor , Bryan Anthony Chan , Hao-Wen Sim , Akina Natori , Eric Xueyu Chen , Geoffrey Liu , Jennifer J. Knox , Jonathan Yeung , Gail Elizabeth Darling , John Kim , Sangeetha Kalimuthu , Elena Elimova , Raymond Woo-Jun Jang

Organizations

Princess Margaret Cancer Centre, Toronto, ON, Canada, Princess Margaret Hospital, Toronto, ON, Canada, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, University of Toronto, Toronto, ON, Canada, Royal Brisbane and Women's Hospital, Brisbane, ON, Canada, The Kinghorn Cancer Centre, St Vincent's Hospital Sydney, Sydney, Australia, St Lukes Int'l Hosp, Koto-Ku, Japan, Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada, University Health Network, Toronto, ON, Canada

Research Funding

Other
Princess Margaret Cancer Centre

Background: Esophageal cancer arising within a previous radiation treatment field (ECRF) is rare. The patterns of disease, treatment and outcomes in these patients (pts) have not been well characterized. Methods: A retrospective analysis was performed for pts treated for esophageal cancer at the Princess Margaret Cancer Centre from 2002-2016. Electronic medical records of all pts with a histologic diagnosis of esophageal cancer occurring within the field of previous radiotherapy were reviewed. The Kaplan-Meier method was used to calculate progression free survival (PFS) and overall survival (OS). Results: Of 31 ECRF pts identified, the most common prior cancer was head and neck (45%), median radiation (RT) dose 50Gy, median time to diagnosis of esophageal cancer 12 years. Features at diagnosis of ECRF included: median age 71 years, 58% male, 87% with performance status (PS) 0-1, 77% squamous cell carcinoma, 19% stage IV. Treatment intent was curative in 16 pts, palliative in 15 (Table). Reasons for palliative treatment were: 40% metastatic, 53% comorbidities/PS, 7% anatomic factors. Of resected pts, 36% had a pT1-2 tumour, 55% pN0, 69% R0. For curative pts, median PFS was 26.2 months (95%CI 10.9-34.4) with a 3 year PFS rate of 35% (95% CI 15-81). Median OS for curative pts was 26.4 months (95%CI 17.8-105.5) with a 3 year OS rate of 43% (95% CI 22-83). Most palliative pts were unable to have chemotherapy due to comorbidities and PS. Median OS for palliative pts was 9.5 months (95% CI 3.6-15.4). Conclusions: Most ECRF pts presented with earlier stage disease; however, more than a third of these could not have aggressive curative treatment due to comorbidities and/or PS. Most curative pts had surgery alone. Few palliative pts had chemotherapy, largely due to poor clinical status. Our data suggest that outcomes in both curative and palliative ECRF pts may be limited by the ability to tolerate standard of care treatments.

Treatment.

Treatment intent Curative n=16 Palliative n=15 Total n=31
Single modality 10 11 21
Chemo
RT
Surgery
0
1
9
4
7
0
4
8
9
Bimodality 6 1 7
Chemo-RT 2 1 3
Surgery and chemo 4 0 4
Supportive 0 3 3

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 328)

Abstract #

328

Poster Bd #

C3

Abstract Disclosures